Nephrogenic Systemic Fibrosis Risk With New MRI Contrast To Be Reviewed
The FDA has asked a panel of outside experts to evaluate the risk of nephrogenic systemic fibrosis (NSF) with a new MRI contrasting agent proposed by Bayer AG.
The FDA has asked a panel of outside experts to evaluate the risk of nephrogenic systemic fibrosis (NSF) with a new MRI contrasting agent proposed by Bayer AG.
Trial has been schedule to begin early next year for a lawsuit involving allegations that a gadolinium-based MRI contrast agent led to the development of nephrogenic systemic fibrosis (NSF), a…
The FDA is banning the use of three major brands of MRI contrast agent on patients with kidney problems, and is forcing other manufacturers to change their labels to bring more…
A Class 1 medical device recall has been issued for GE Healthcare Aisys and Avance Anesthesia Systems, which can fail to provide ventilation for patients under the affects of anesthetics.